Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Radiol. Oct 28, 2014; 6(10): 741-755
Published online Oct 28, 2014. doi: 10.4329/wjr.v6.i10.741
Published online Oct 28, 2014. doi: 10.4329/wjr.v6.i10.741
2-deoxy-2-(18F)fluoro-D-glucose positron emission tomography/computed tomography imaging in paediatric oncology
John Freebody, Eva A Wegner, Monica A Rossleigh, Department of Nuclear Medicine and PET, The Prince of Wales and Sydney Children’s Hospitals, Randwick, NSW 2031, Australia
Author contributions: All authors contributed to the writing and editing of this manuscript.
Correspondence to: John Freebody, BSc MBBS, Department of Nuclear Medicine and PET, The Prince of Wales and Sydney Children’s Hospitals, Barker St, Randwick, NSW 2031, Australia. john.freebody@health.nsw.gov.au
Telephone: +61-2-93822200 Fax: +61-2-93822235
Received: December 26, 2013
Revised: March 5, 2014
Accepted: September 16, 2014
Published online: October 28, 2014
Revised: March 5, 2014
Accepted: September 16, 2014
Published online: October 28, 2014
Core Tip
Core tip: Positron emission tomography/computed tomography has emerged as a powerful and important tool in the assessment of a variety of childhood cancers and can impact significantly on patient management. Further prospective studies will more clearly delineate the precise role of this modality in the assessment of individual malignancies. Accurate image interpretation requires a thorough understanding of the normal variants of uptake unique to children.